A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 21 Apr 2017
At a glance
- Drugs E 2730 (Primary)
- Indications Epilepsy; Neurological disorders
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Eisai Inc
- 17 Apr 2017 Planned End Date changed from 1 Apr 2017 to 18 May 2017.
- 17 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 23 Feb 2017 New trial record